Randomized Controlled Trial Evaluating Response to Metformin Versus Standard Therapy in the Treatment of Adolescents with Polycystic Ovary Syndrome

Allen, Holley; Mazzoni, Cristina; Heptulla, Rubina A.; Murray, Mary; Miller, Nancy Houston; Koenigs, Laura; Reiter, Edward O.

doi:10.1515/jpem.2005.18.8.761

Cited by 82 publications

(64 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[39][40][41][42] Table 1 reveals the summary of all included studies, Table 2 reveals baseline characteristics for all outcomes, and Supplemental Tables 7, 8, 9, and 10 reveal a detailed summary of each study. All studies used the NIH criteria to diagnose PCOS.…”

Section: Study Characteristicsmentioning

confidence: 99%

Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…81 Metformin is also effective in reducing the incidence of diabetes in those at high risk 80 and has been used with some success in management of symptoms of PCOS in adolescents. [82][83][84] However there is a lack of large, randomized controlled trials to assess efficacy of symptom control in adolescents and no prospective study, even in adults, to examine the long-term effects of metformin in prevention or reduction of metabolic complications of PCOS. Recently, an impressively large and well-conducted trial of metformin as an adjunct to clomiphene treatment for induction of ovulation has shown no benefit of metformin.…”

Section: Management Of Pcos In Adolescentsmentioning

confidence: 99%

Polycystic ovary syndrome in adolescents

2008

View full text Add to dashboard Cite

Background: Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women and typically presents during adolescence. The clinical and biochemical presentation is heterogeneous, but elevated serum concentrations of androgens are the most consistent biochemical abnormality and may be considered to be the hallmark of the syndrome. Many women with PCOS also have insulin resistance and hyperinsulinaemia, which may contribute to the clinical and endocrine abnormalities. The aetiology of PCOS is not clear but studies in the Rhesus monkey suggest that exposure to excess androgen during intrauterine life results in many of the features of human PCOS, including ovarian dysfunction, abnormal LH secretion and insulin resistance. Objective: To review the studies from the literature, including those of the author, regarding aetiology, presentation and management of PCOS in adolescents. Results and conclusions: We have proposed that PCOS in adolescents arises as a result of a genetically determined disorder of ovarian function that results in hyper-secretion of androgens, possibly during fetal life and also during physiological activation of the hypothalamic-pituitary-ovarian in infancy and at the onset of puberty. There is plentiful evidence for a genetic basis for PCOS (it appears to be a complex endocrine disorder resulting from the effects of a several genes), but environmental factors, notably nutrition, influence the clinical and biochemical phenotype. Obesity unmasks or amplifies symptoms, endocrine and metabolic abnormalities. The increasing incidence of childhood obesity has resulted in an alarming Increase not only in distressing symptoms but also impaired glucose tolerance and even diabetes among adolescent girls with PCOS. The search for PCOS genes in this condition, that is not only heterogeneous but also presents only in women of reproductive age, is not straightforward and has produced few convincing candidates so far. In due course, however, identification of the major susceptibility loci is likely to provide key insight into the aetiology of the syndrome and improve diagnosis and management.

show abstract

“…It is not currently approved for use in obesity or insulin resistance in adolescents, and its use for these indications has been 54 which demonstrated a 31% reduction in risk of type 2 diabetes among high risk adults with metformin therapy. Use of metformin to treat obesity-related comorbidities associated with insulin resistance, such as polycystic ovarian syndrome (PCOS) 55 and nonalcoholic steatohepatitis, 56 has also been under investigation. The two small meta-analyses of randomized trials of metformin therapy in pediatrics used overlapping but not equivalent sets of studies and arrived at differing conclusions.…”

Section: Metforminmentioning

confidence: 99%

“…115,117 It can also improve ovulation in young women with polycystic ovarian syndrome. 55 In addition to the low risk of hypoglycemia with metformin, these characteristics have made metformin the first-line oral medication for overweight adults with type 2 diabetes. 115 …”

Section: Dovepressmentioning

confidence: 99%

Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy

Rhodes¹,

Fleischman²

2009

DMSOTT

View full text Add to dashboard Cite

Randomized Controlled Trial Evaluating Response to Metformin Versus Standard Therapy in the Treatment of Adolescents with Polycystic Ovary Syndrome

Cited by 82 publications

References 38 publications

Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis

Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis

Polycystic ovary syndrome in adolescents

Management of obesity, insulin resistance and type 2 diabetes in children: consensus and controversy

Contact Info

Product

Resources

About